Mylan pursuit hasn't stopped Perrigo from scouting its own deals: CEO

Perrigo CEO Joseph Papa

Perrigo may be embroiled in a takeover fight with pursuer Mylan ($MYL), but that hasn't stopped it from pursuing tie-ups of its own--even $1 billion-plus buys.

"We, as a company, are very active in M&A," CEO Joseph Papa told Bloomberg. "We're going to continue to do more deals."

While there's distinct potential for buyouts in the $100 million to $1 billion range, "it doesn't mean we won't look at even larger transactions," he told the news service.

Perrigo has lately been an active player in the M&A arena, in June inking an all-cash deal for a portfolio of older OTC products from market leader GlaxoSmithKline ($GSK). That move followed last year's $4.5 billion deal for Belgium's Omega Pharma and 2013's $8.6 billion transaction for Elan, which allowed the company to complete a tax inversion.

As Bloomberg notes, though, the Irish Takeover Panel could rein Perrigo in if the body decides the company is aiming specifically to block Mylan in its attempts to acquire the company. Perrigo hasn't been shy about saying it doesn't want to be Mylan's next target, slamming the drugmaker's proposal repeatedly and questioning its leaders' "very troubling corporate governance values."

Mylan, though, has stood by its offer, and Friday, its shareholders will get the chance to decide whether the attempted hostile takeover moves forward. If its own shareholders approve, Mylan's leaders are "confident that Perrigo shareholders will then support this transaction given the opportunities for value-creation presented by the combination," Chairman Robert Coury said in a Tuesday statement.

- get more from Bloomberg

Special Reports: Top 10 generics makers by 2012 revenue - Mylan | Pharma's top 10 M&A deals of 2014 - Mylan/Abbott Laboratories established products

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.